Logo Image
News|Podcasts|April 22, 2026

The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move

Cell therapy process design, leronlimab cancer data, and Amneal’s biosimilars strategy highlight key biopharma trends in manufacturing and innovation.

Today on The BioPharm Brief, we’re looking at three developments shaping the future of biopharma—from early-stage process design challenges to clinical oncology signals and strategic moves in the biosimilars market.

First, a closer look at cell and gene therapy development highlights a persistent issue: success often hinges on decisions made very early in process design. Experts emphasize that poorly defined upstream and downstream strategies can create major bottlenecks later in scale-up and manufacturing. The takeaway is clear—early integration of process development, analytics, and CMC planning isn’t just helpful, it’s essential for avoiding costly delays and ensuring therapies can reach patients efficiently.

In clinical news, leronlimab is showing early signs of activity in metastatic colorectal cancer. Preliminary data presented at AACR 2026 point to both clinical responses and biomarker engagement, suggesting the therapy may have potential in a difficult-to-treat population. While still early-stage, these findings add to the growing interest in immune-modulating approaches beyond traditional checkpoint inhibitors.

And finally, on the business front, Amneal Pharmaceuticals is expanding its footprint in biosimilars through the acquisition of Kashiv BioSciences. This move creates a more integrated platform spanning development, manufacturing, and commercialization. It reflects a broader industry trend toward vertical integration as companies look to compete more effectively in the increasingly complex biosimilars market.

Taken together, today’s stories highlight a common theme: success in biopharma increasingly depends on connecting early science, clinical insight, and scalable manufacturing strategy.

  • Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

    KEY TAKEAWAYS
  • Amneal’s Kashiv acquisition signals a push toward integrated biosimilars development and manufacturing
  • Early process design and CMC planning are critical to scaling cell and gene therapies successfully
  • Leronlimab shows early clinical and biomarker activity in metastatic colorectal cancer

Related to this article

View more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more